Musings on the latest developments in AIDS vaccine research from the IAVI Report team. |
|
| Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XsnLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | FileType | xsn | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document.2 | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document.3 | 255 | | Edit in Browser | /_layouts/images/icxddoc.gif | /IRblog/_layouts/formserver.aspx?XmlLocation={ItemUrl}&OpenIn=Browser | 0x0 | 0x1 | ProgId | InfoPath.Document.4 | 255 | | View in Web Browser | /_layouts/images/ichtmxls.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&DefaultItemOpen=1 | 0x0 | 0x1 | FileType | xlsx | 255 | | View in Web Browser | /_layouts/images/ichtmxls.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&DefaultItemOpen=1 | 0x0 | 0x1 | FileType | xlsb | 255 | | Snapshot in Excel | /_layouts/images/ewr134.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&Snapshot=1 | 0x0 | 0x1 | FileType | xlsx | 256 | | Snapshot in Excel | /_layouts/images/ewr134.gif | /IRblog/_layouts/xlviewer.aspx?listguid={ListId}&itemid={ItemId}&Snapshot=1 | 0x0 | 0x1 | FileType | xlsb | 256 |
|
|
|
|
|
|
IAVIReport.org > Blog
|
|
|
July 21, 2010 05:35 PMThe discussion about test and treat has picked up steam over the past few years, partly because of mathematical models that show this strategy, which calls for universal HIV testing and immediate treatment for all those infected, could dramatically decrease HIV incidence. However, today in Vienna, researchers emphasized the need for more data on using antiretroviral treatment as a prevention strategy.
July 20, 2010 11:25 AM
You need not look further than the headlines today for the biggest news to emerge from the International AIDS Conference in Vienna. For the first time, a microbicide candidate was shown to reduce the risk of sexual transmission of HIV in women. The candidate, a 1% gel formulation of the antiretroviral tenofovir, reduced the risk of HIV infection by 39% in a South African trial known as CAPRISA 004, which involved 889 women.
July 19, 2010 10:21 AM
At the opening session of the XVIII International AIDS Conference in Vienna, the stage was set for the major themes of the conference.
July 18, 2010 02:51 PM
Welcome to the IAVI Report blog, kicking off at the XVIII International AIDS Conference in Vienna.
While most of the world is all atwitter, we are excited to finally be launching the IAVI Report blog.
The goal of this blog is to provide more immediate updates on AIDS vaccine research and development than our bi-monthly publication allows. This means we will be blogging live from several conferences and meetings, including the IAC that just opened today. |
|
|
|
|
|